2024-519660-40-00CompletedPhase 1
A study comparing the new drug PG413 produced by Celon Pharma SA with the drug Eliquis available on the market in healthy volunteers.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Mar 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- First submitted
- 16 Dec 2024
- Start date
- 31 Mar 2025
- Lead sponsor
- Celon Pharma S.A.
- EU CT number
- 2024-519660-40-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 38
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BioResearch Group sp. z o.o. | Nadarzyn | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.